Sees revenue to be at least $200 M reflecting performance to date in our GLP-1 weight management program exceeding previous guidance, raised from previous guidance of $195M to $205M Adjusted EBITDA guidance of between $18M and $22M, consistent with previous guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LFMD:
- LifeMD Reports Fourth Quarter 2023 Results
- Lifemd, Inc. (LFMD) Q4 Earnings Cheat Sheet
- Medifast price target lowered to $40 from $67 at DA Davidson
- LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
